Dividing CKD stage 3 into G3a and G3b could better predict the prognosis of IgA nephropathy
Fig 2
Survival curves of IgAN patients with CKD stage 3 and patients of different subgroups.
(a) Patients with CKD stage 3. (b) Patients with CKD stage G3a (dotted line) or G3b (solid line) (log-rank P<0.001). Patients with G3a (dotted line) or G3b stage (solid line) based on (c) hypertension (G3a: n = 92, G3b: n = 98) (log-rank P<0.001), (d) non-hypertension (G3a: n = 117, G3b: n = 83) (log-rank P<0.001), (e) proteinuria ≥3.5 g/d (G3a: n = 48, G3b: n = 56) (log-rank P<0.001), (f) proteinuria< 3.5 g/d (G3a: n = 161, G3b: n = 125) (log-rank P<0.001), (g) anemia (G3a: n = 51, G3b: n = 64) (log-rank P<0.001), (h) non-anemia (G3a: n = 158, G3b: n = 117) (log-rank P<0.001), (i) serum phosphorus ≥1.45 mmol/L (G3a: n = 33, G3b: n = 67) (log-rank P<0.001), (j) serum phosphorus <1.45 mmol/L (G3a: n = 176, G3b: n = 114) (log-rank P<0.001). Abbreviations: IgAN, IgA nephropathy; CKD, chronic kidney disease.